普伐他汀的非调脂作用

Effect of Pravastatin on plasma levels of hs CRP,ET in elderly patients with coronary heart disease and its non-lipid function

目的观察老年冠心病患者使用普伐他汀治疗8周后,血脂、高敏C反应蛋白(hs CRP),内皮素(Endotheli-al,ET)的变化。方法对42例伴有高脂血症的老年冠心病患者每日服用10 mg普伐他汀8周,测定其服药前后血脂[总胆固醇(TC)、三酰甘油(TG),低密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇(HDL-C)],hs CRP,ET水平并做统计学分析。结果普伐他汀可有效地降低老年冠心病伴高脂血症患者血脂TC、TG、LDL-C和hs CRP、ET(P<0.01,P<0.05),HDL-C有较显著升高(P<0.05),而且普伐他汀引起的血hs CRP、ET的降低分别与TC(r=0.196;r=0.135)、LDL-C(r=0.227;r=0.176,)、TG(r=0.145;r=0.304,P=0.05)的下降之间无相关关系。结论老年冠心病患者服用普伐他汀治疗后,可明显控制血浆hs CRP、ET水平,具有独立于降脂作用之外的抑制炎症,改善内皮功能,稳定斑块的作用。

AIM To observe the changes of plasma levels of high sensitive C-reactive protein （ hs CRP） and endothelial （ET） following 8-week administration of Pravastatin in elderly patients with coronary heart disease （CHD）. METHODS Forty-two elderly patients with CHD and hyperlipidemia were treated with Pravastatin for 8 weeks. Before and after the treatment, the plasma levels of TC, LDL-C, HDL- C, TG, hs CRP and ET were detected and compared. RESULTS After 8 weeks of treatment, the plasma levels of TC, TG, LDL-C, hs CRP and ET were significantly decreased （P 〈 0.01, P 〈 0.05 ） while HDL-C increased （P 〈 0.05）. There was no relation between the decreasing values of TC, hs CRP and ET and those of TC （r=0. 196; r=0. 135 ）, LDL-C （r =0.227; r=0. 176 ） and TG （r=0. 145; r= 0. 304 P =0.05）. CONCLUSION HMG-COA reductase inhibitors can reduce the levels of inflamma- tory factors and they may have some non-lipid effects on improving the function of vascular endothelium, which plaque, independent of lipid-lowering effects. the inhibitive activities of inflammatory factors, may promote the stabilization of atherosclerotic